Provisional experiences with the combination of L-dopa and L-deprenyl
In a retrospective study three different groups of patients are compared: patients on L-dopa on its own, patients on L-dopa plus L-deprenyl and patients on L-dopa plus Ergot-derivatives. The aim of the study was to find out if there was any advantage gained from one of these strategies. The study showed that the combination-therapy was superior to L-dopa alone; it did not matter whether L-dopa was combined with L-deprenyl or with an Ergot-derivative.
KeywordsFederal Republic Motor Movement Toxic Radical Nigrostriatal Dopaminergic Neuron Provisional Experience
Unable to display preview. Download preview PDF.
- Csanda E, Antal J, Fornadi F (1980) Clinical experience in extrapyramidal diseases with selective MAO-B-inhibitor, L-deprenyl. In: Magyar K (ed) Monoamine exidase and their selective inhibitors. Akadémiai Kiadó, Budapest/Pergamon Press, Oxford, pp 127–132Google Scholar
- Knoll J (1987) R-(-)-deprenyl (selegeline, movergan®) facilitates the activity of the nigrostriatal dopaminergic neuron. J Neural Transm [Suppl] 25: 45–66Google Scholar
- Lees AJ (1987) Surrent controversies in the use of selegiline hydrochloride. J Neural Transm [Suppl] 25: 157–162Google Scholar
- Marsden CD, Sandler M (1986) The MPTP story: an introduction. J Neural Transm [Suppl] 20: 1–3Google Scholar
- Sandler M, Willoughby J, Glover V, Gibb C (1987) Selegiline and the prophylaxis of Parkinson’s disease. J Neural Transm [Suppl] 25: 35–43Google Scholar
- Tetrud JW, Langston JW (1987) R-(-)-deprenyl as a possible protective agent in Parkinson’s disease. J Neural Transm [Suppl] 25: 69–79Google Scholar
- Ulm G, Fornadi F (1987) R-(-)-deprenyl in the treatment of end-of-dose akinesia. J Neural Transm [Suppl] 25: 163–172Google Scholar